Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Rong-Hui Zheng"'
Autor:
Jin-Can Chen, Chao Fang, Rong-Hui Zheng, Ming-Liang Chen, Duck-Hyun Kim, Young-Hwan Lee, Christyn Bailey, Ke-Jian Wang, Jae-Seong Lee, Jun Bo
Publikováno v:
Ecotoxicology and Environmental Safety, Vol 241, Iss , Pp 113843- (2022)
Microplastics (MPs), due to their impacts on the ecosystem and their integration into the food web either through trophic transfer or ingestion directly from the ambient environment, are an emerging class of environmental contaminants posing a great
Externí odkaz:
https://doaj.org/article/c108d988c7314c59a6a427c0339f6497
Autor:
Ze-Jiang Zhan, Wen-Yu Yao, Fang Zhang, Wen-Ze Qiu, Kai- Liao, Jian-Hui Feng, Jin-Yun Tan, Hui Liu, Tai-Ze Yuan, Rong-Hui Zheng, Ya-Wei Yuan
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
BackgroundThe optimal second-line systemic treatment model for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains controversial. A Bayesian network meta-analysis (NMA) was performed to address this issue with regard
Externí odkaz:
https://doaj.org/article/a7a9fb44ce8a4ac6aab708bf08210b98
Autor:
Xiao-Hong Xie, Ze-Jiang Zhan, Yin-Yin Qin, Ju-Hong Jiang, Wei-Qiang Yin, Rong-Hui Zheng, Shi-Yue Li, Cheng-Zhi Zhou
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The treatment of anaplastic lymphoma kinase (ALK)-positive locally advanced non-small-cell lung cancer (NSCLC) is challenging because there is no randomized controlled trial has been reported. The value of neoadjuvant and adjuvant targeted therapy re
Externí odkaz:
https://doaj.org/article/ce4a235ef7d04f10b2512075f2b4cd23
Autor:
Ze-Jiang Zhan, Rui-Xin Zhang, Wen-Ze Qiu, Guo Li, Tai-Ze Yuan, Zhong-Yuan Liu, Kai Liao, Ya-Wei Yuan, Hao-Yun Tao, Rong-Hui Zheng
Publikováno v:
Journal of Cancer
Aims: This study aimed to investigate the clinical value of induction chemotherapy (IC) with docetaxel, 5-fluorouracil plus nedaplatin followed by concurrent chemoradiotherapy (CCRT) with nedaplatin for locoregional advanced nasopharyngeal carcinoma
Objective: This study aimed to explore the clinical value of adjuvant chemotherapy (ACT) in locoregionally advanced nasopharyngeal carcinoma (LANC) following concurrent chemoradiotherapy (CCRT) and induction chemotherapy (ICT).Methods: We included 83
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b4ee1533530aac0ad9ade79fab99fcbb
https://doi.org/10.21203/rs.3.rs-848732/v1
https://doi.org/10.21203/rs.3.rs-848732/v1
Autor:
Xiuping Zhang, Huanhuan Zhang, Baoqiong Liu, Rong-hui Zheng, Qiong Zhang, Jin Deng, Yin Liang, Taize Yuan
Publikováno v:
Medical Oncology. 31
Metastasis-associated protein 1 (MTA1) is related to tumour metastasis and poor prognosis in various human cancers. The aim of this study was to investigate the expression of MTA1 in nasopharyngeal carcinoma (NPC) and explore the prognostic value of
Autor:
Rong-hui Zheng, Jin Deng, Qiong Zhang, Xiuping Zhang, Yin Liang, Jian Li, Taize Yuan, Qiong-Fen Tang, Huanhuan Zhang, Lai-ji Huang
Publikováno v:
The Laryngoscope. 124(5)
Objectives/Hypothesis The KiSS-1 gene has been reported to serve as a metastasis suppressor gene in various human malignancies. However, no information is available regarding the role of the KiSS-1 gene or its gene product kisspeptin in nasopharyngea
Autor:
Jian Li, Yin Liang, Xiu‑Ping Zhang, Huan‑Huan Zhang, Guo‑Feng Xie, Tai‑Ze Yuan, Rong‑Hui Zheng, Lai‑Ji Huang, Jia‑Cai Ye
Publikováno v:
Experimental and Therapeutic Medicine
The aim of this study was to explore the effects of erlotinib combined with radiation on human nasopharyngeal carcinoma (NPC) radiosensitivity using the CNE1 and CNE2 cell lines. Human NPC cells were treated with erlotinib and/or radiation. The effec
Autor:
Rong-hui, Zheng, Xun-xing, Guan, Xiu-ping, Zhang, Zhen-yu, He, Lai-ji, Huang, Zhi-wei, Liao, Qin, Tong
Publikováno v:
Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 30(3)
To investigate the correlation of prolactin receptor (PRL-R) expression to estrogen receptor (ER) and progesterone receptor (PR) expressions in primary breast cancer.For 130 female patients with breast cancer (median age 46 years), PRL-R expression i